Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Imagion Biosystems Ltd. ( (AU:IBX) ).
Imagion Biosystems has secured an additional US$300,000 in short‑term funding from a fund managed by U.S.‑based C/M Capital Partners, under its existing convertible securities framework originally established with Mercer Street Global Opportunity Fund. The deal follows a partial novation of the prior agreement to C/M Capital Master Fund and underscores continued investor backing as the company awaits U.S. FDA review of its Investigational New Drug application.
Alongside the new facility, Imagion and Mercer Street have amended key terms of the convertible securities agreement, extending the maturity of notes previously due before this announcement to 31 December 2026. Any new notes issued will now carry an 18‑month maturity from issuance and a floor conversion price of A$0.025, changes that ease near‑term repayment pressure while providing clearer financing terms for existing shareholders and prospective investors.
The most recent analyst rating on (AU:IBX) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is a clinical‑stage medical imaging company focused on transforming cancer diagnosis and treatment through its proprietary MagSense technology. The company is developing first‑of‑its‑class molecular MRI imaging agents based on non‑radioactive magnetic nanoparticles to enable earlier, more precise detection of cancers, including HER2‑positive breast, prostate and ovarian cancers.
Average Trading Volume: 2,076,170
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.79M
See more data about IBX stock on TipRanks’ Stock Analysis page.